Considering the patient's medication regimen and the known interactions with CYP enzymes, which of the following clinical considerations is most appropriate when managing this patient's anticoagulation therapy?
Discontinue clopidogrel due to its interaction with Verapamil, which can lead to increased bleeding risk. Administer a higher dose of Alteplase due to potential decreased efficacy from interaction with Warfarin. Monitor INR closely and adjust warfarin dose due to potential interaction with Verapamil, which can affect CYP3A4 and CYP2C9 activity. Increase the dose of Digoxin due to potential competitive inhibition by Verapamil on CYP2D6.